474 related articles for article (PubMed ID: 1582860)
21. High PAI activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of myocardial infarction.
Ihnken K; Speiser W; Ruf W; Thiel W; Schlepper M; Müller-Berghaus G
Ann Hematol; 1993 Nov; 67(5):237-44. PubMed ID: 8241347
[TBL] [Abstract][Full Text] [Related]
22. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
Juhan-Vague I; Valadier J; Alessi MC; Aillaud MF; Ansaldi J; Philip-Joet C; Holvoet P; Serradimigni A; Collen D
Thromb Haemost; 1987 Feb; 57(1):67-72. PubMed ID: 3109059
[TBL] [Abstract][Full Text] [Related]
23. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
[TBL] [Abstract][Full Text] [Related]
24. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
[TBL] [Abstract][Full Text] [Related]
25. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
[TBL] [Abstract][Full Text] [Related]
26. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
28. [Tissue plasminogen activator, its inhibitor and other parameters of fibrinolysis in blood of patients operated for mild hypertrophy of the prostate].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F; Cwiklińska-Jurkowska M
Pol Tyg Lek; 1992 Dec 7-14; 47(49-50):1096-7. PubMed ID: 1284828
[TBL] [Abstract][Full Text] [Related]
29. Transmyocardial fibrinolytic activity in patients with unstable angina pectoris.
Daniel WC; Meidell RS; Hillis LD; Lange RA
Coron Artery Dis; 1996 Jan; 7(1):45-9. PubMed ID: 8773432
[TBL] [Abstract][Full Text] [Related]
30. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
31. Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction.
Speidl WS; Nikfardjam M; Niessner A; Zeiner A; Jordanova N; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
Thromb Res; 2007; 119(3):331-6. PubMed ID: 16616324
[TBL] [Abstract][Full Text] [Related]
32. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
[TBL] [Abstract][Full Text] [Related]
33. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion.
Speidl WS; Zeiner A; Nikfardjam M; Geppert A; Jordanova N; Niessner A; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
J Am Coll Cardiol; 2005 Jan; 45(1):30-4. PubMed ID: 15629369
[TBL] [Abstract][Full Text] [Related]
34. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis].
Opatrný K; Vít L; Opatrná S; Sulková S; Bodláková B
Cas Lek Cesk; 1994 May; 133(11):346-9. PubMed ID: 8004664
[TBL] [Abstract][Full Text] [Related]
35. Changes in plasma levels of tissue plasminogen activator and its inhibitor in aged myocardial infarction patients.
Chen HZ; Jia HY; Song HY; Wang JY
Chin Med J (Engl); 1990 Jul; 103(7):541-5. PubMed ID: 2119970
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the fibrinolytic response to desmopressin acetate (DDAVP) infusion versus venous occlusion in patients with coronary artery disease.
Duprez D; Baele G; De Buyzere M; Vandenbroecke P; Clement DL
Eur Heart J; 1991 Jul; 12(7):800-2. PubMed ID: 1909628
[TBL] [Abstract][Full Text] [Related]
37. Plasminogen activator inhibitor (PAI) in obese men and obese women.
Cucuianu M; Lanczek M; Roman S
Rom J Intern Med; 1993; 31(3):183-92. PubMed ID: 8130756
[TBL] [Abstract][Full Text] [Related]
38. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
39. Tissue plasminogen activator release in chronic venous hypertension due to heart failure.
Keber I; Keber D; Stegnar M; Vene N
Thromb Haemost; 1992 Sep; 68(3):321-4. PubMed ID: 1440498
[TBL] [Abstract][Full Text] [Related]
40. Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease.
Rydzewski A; Sakata K; Kobayashi A; Yamazaki N; Urano T; Takada Y; Takada A
Haemostasis; 1990; 20(5):305-12. PubMed ID: 2127039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
